SEHK:3738
SEHK:3738Software

Undiscovered Gems In Asia To Explore This November 2025

As global markets navigate the complexities of AI-related concerns and fluctuating economic indicators, Asian markets have mirrored these challenges with notable declines in key indices. Despite this backdrop, the search for promising opportunities continues, particularly among small-cap stocks that may offer unique growth potential in a volatile environment. Identifying a good stock often involves looking for companies with strong fundamentals and innovative capabilities that can thrive...
SEHK:3939
SEHK:3939Metals and Mining

A Look at Wanguo Gold Group (SEHK:3939) Valuation Following Gold Ridge Mine Feasibility Study Release

Wanguo Gold Group (SEHK:3939) just released a thorough summary of the Gold Ridge Mine feasibility study in the Solomon Islands, outlining both geology and resource estimates. The project’s scale and development prospects present intriguing implications for shareholders. See our latest analysis for Wanguo Gold Group. Wanguo Gold Group’s recent announcement about the Gold Ridge Mine has sparked renewed investor enthusiasm, with the share price rallying 5.08% in just one day and climbing more...
SEHK:6618
SEHK:6618Consumer Retailing

JD Health (SEHK:6618): Valuation Insights Following New Partnership to Boost Chronic Disease Services and Online Reach

JD Health International (SEHK:6618) has partnered with ClouDr Group Limited to expand its online sales presence and improve chronic disease management services. The collaboration aims to combine the scale of JD Health with the specialized medical expertise of ClouDr. See our latest analysis for JD Health International. JD Health International’s latest partnership comes on the heels of a stellar run, with its share price soaring 135.61% year-to-date. While there has been a modest dip over the...
SEHK:6881
SEHK:6881Capital Markets

Successful RMB 5 Billion Bond Issuance Might Change the Case for Investing in China Galaxy Securities (SEHK:6881)

On November 19, 2025, China Galaxy Securities announced the completion of a non-public issuance of RMB 5 billion corporate bonds, split between two-year and three-year maturities to professional investors, with proceeds allocated for repaying matured bonds. Strong participation from several underwriters and their affiliated institutions highlighted significant institutional confidence in the company's ability to manage its debt obligations. We'll explore how this successful bond issuance and...
SEHK:1672
SEHK:1672Biotechs

Will Promising Preclinical Results in Obesity Candidates Reshape Ascletis Pharma's (SEHK:1672) Innovation Narrative?

Ascletis Pharma announced that its co-formulation of ASC36 and ASC35, two once-monthly next-generation peptide drug candidates, showed promising efficacy and chemical stability in preclinical obesity studies, with plans to submit an Investigational New Drug Application to the US FDA in the second quarter of 2026. This advancement leverages Ascletis’ proprietary AI-assisted and ultra-long-acting drug technologies, aiming to address unmet needs in obesity treatment with differentiated dosing...
SEHK:823
SEHK:823Retail REITs

Assessing Link REIT (SEHK:823) Valuation Following Latest Earnings and Interim Distribution Update

Link Real Estate Investment Trust (SEHK:823) just released earnings for the half year through September 2025, showing a narrower loss compared to last year but also revealing a slight dip in sales. Alongside the results, an interim distribution was announced with important payout dates for unitholders. See our latest analysis for Link Real Estate Investment Trust. After a tough week that saw Link Real Estate Investment Trust’s share price slide more than 12%, recent earnings and a new interim...
SEHK:9926
SEHK:9926Biotechs

Does Akeso’s (SEHK:9926) First Alzheimer’s Bispecific Antibody Approval Reinvent Its Innovation Narrative?

Earlier this month, Akeso, Inc. announced that its novel bispecific antibody AK152 received approval from the National Medical Products Administration (NMPA) to begin clinical trials for Alzheimer's Disease, marking the first such therapy of its kind developed in China for disease modification. This milestone also signifies Akeso's entry into innovative central nervous system therapeutics, leveraging enhanced brain penetration and robust preclinical results for potential next-generation...
SEHK:200
SEHK:200Hospitality

Melco International Development (SEHK:200): Exploring Valuation After House of Dancing Water Wins TITAN Brand Awards

Melco International Development (SEHK:200) is in focus after its House of Dancing Water production earned top honors for brand awareness and marketing at the 2025 TITAN Brand Awards. Outstanding social media engagement has captured investors’ interest. See our latest analysis for Melco International Development. Melco International Development’s recent accolades have added fresh energy to its shares, reflected in a robust 41% total return over the last year. Short-term momentum has been...
SEHK:354
SEHK:354IT

Chinasoft’s OpenHarmony and RISC-V Alliance Might Change the Case for Investing in Chinasoft (SEHK:354)

Chinasoft International recently announced a strategic cooperation agreement with Shenzhen Kaihong Digital Industry Development and Beijing ESWIN Computing Technology to co-develop a dual-open-source ecosystem based on "OpenHarmony + RISC-V." This alliance aims to create a comprehensive domestic software-hardware ecosystem that could challenge existing global technology architectures and standards. We’ll explore how this push into an independent "OpenHarmony + RISC-V" platform could shape...
SEHK:688
SEHK:688Real Estate

China Overseas Land & Investment (SEHK:688): Evaluating Valuation Following Double Coast III Launch Momentum

China Overseas Land & Investment (SEHK:688) is in the spotlight this week following the release of the first price list for Double Coast III in Kai Tak. This move reflects ongoing property development activity and signals future sales momentum for the group. See our latest analysis for China Overseas Land & Investment. The release of the Double Coast III price list has clearly caught investors’ attention, as China Overseas Land & Investment’s share price is up 14.8% year-to-date and total...